Compare · ABIO vs LNTH
ABIO vs LNTH
Side-by-side comparison of ARCA biopharma Inc. (ABIO) and Lantheus Holdings Inc. (LNTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABIO and LNTH operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH is the larger of the two at $1.68B, about 65.7x ABIO ($25.5M).
- LNTH has hit the wire 2 times in the past 4 weeks while ABIO has been quiet.
- LNTH has more recent analyst coverage (17 ratings vs 0 for ABIO).
- Company
- ARCA biopharma Inc.
- Lantheus Holdings Inc.
- Price
- $2.45-2.78%
- $84.39+1.93%
- Market cap
- $25.5M
- $1.68B
- 1M return
- -
- +11.61%
- 1Y return
- -
- -17.93%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 17
ARCA biopharma Inc.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Latest ABIO
- Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.
- Director Fairmount Funds Management Llc was granted 275,000 shares (SEC Form 4)
- ARCA biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SC 13D filed by ARCA biopharma Inc.
- New insider Fairmount Funds Management Llc claimed ownership of 2,936,922 shares (SEC Form 3)
- New insider Turtle Cameron claimed ownership of 85,233 shares (SEC Form 3)
- SEC Form 3 filed by new insider Kulkarni Samarth
- SEC Form 3 filed by new insider Dambkowski Carl
- SEC Form 3 filed by new insider Ball Kristine M
- SEC Form 3 filed by new insider Quinlan Paul T
Latest LNTH
- Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time
- SEC Form 4 filed by Niedzwiecki Daniel
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- SEC Form DEFA14A filed by Lantheus Holdings Inc.
- SEC Form DEF 14A filed by Lantheus Holdings Inc.
- Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
- SEC Form PRE 14A filed by Lantheus Holdings Inc.
- Officer Niedzwiecki Daniel was granted 36,692 shares and covered exercise/tax liability with 1,283 shares, increasing direct ownership by 42% to 119,376 units (SEC Form 4)
- Officer Dinkelborg Ludger was granted 20,966 shares, increasing direct ownership by 142% to 35,731 units (SEC Form 4)
- CFO and Treasurer Marshall Robert J. Jr. was granted 38,002 shares and covered exercise/tax liability with 1,182 shares, increasing direct ownership by 43% to 122,792 units (SEC Form 4)